Session – How to ensure clarity and communication of goals and expectations for successful technology transfer during drug development with your CDMO Nicholas Dunwoody has served as Vice President, CMC at Tetraphase Pharmaceuticals since April 2015, responsible for all CMC functional areas including clinical supply chain. Dr. Dunwoody joined Tetraphase in June 2008, and in his tenure has held various positions in Analytical Chemistry and Formulation Sciences. Prior to joining Tetraphase, Dr. Dunwoody served as Director of Analytical Chemistry and Pharmaceutical Services at Nucryst Pharmaceuticals, Inc. from 2004-2008. Dr. Dunwoody began his professional career as an investigator at Vertex Pharmaceuticals, from 2000-2004. Notable achievements in his career include the development of 14 small molecule products, one biologic pharmaceutical product and a series of nano-materials in pharmaceutical and medical device applications. Dr. Dunwoody has been pivotal in the development of Tetraphase’s first commercial product, XERAVATM (eravacycline for injection), launched in September 2018 for the treatment of complicated intra-abdominal infections (cIAI).